Purpose : High-density lipoprotein cholesterol (HDL-C) levels are a strong inverse predictor of cardiovascular events. We investigated the significance of HDL-C level after stain therapy on the outcomes of patients who underwent drug eluting stent (DES) implantation for coronary artery disease. Method : 764 patients who underwent DES deployment were prospectively enrolled from September 2003 to December 2006. We were able to obtain lipid panel of 378 patients after statin therapy for 6 months and compare clinical outcomes according to HDL-C level at 6 months. Low HDL cholesterol level was defined as HDL-C level under 40 mg per deciliter for men or 50 mg per deciliter for women. The primary end point was a composite of major adverse cardiac events (MACE) including cardiac death, myocardial infarction, and target vessel revascularization. Results : Mean follow-up duration was 651 짹 233 days. 201 patients had low HDL-C level and 177 patients had high HDL-C level. High HDL-C after statin therapy was a significant independent inverse predictor of MACE (adjusted hazard ratio 0.390, 95% confidence interval[CI] 0.179 to 0.850, p=0.018). Furthermore, every 10-mg/dl increase in HDL-C at 6 months was associated with 40% (95% CI 9% to 61%, p=0.016) decrease of MACE after adjustment for other risk factors. Conclusions : HDL-C level after statin therapy is associated with cardiovascular events in patients with DES implantation, suggesting next therapeutic target for coronary artery disease.